Advancing Prediction of Nitrosamine Carcinogenicity Potency

This week, Dr. Kevin Cross from Instem is presenting at the 2022 Genetic Toxicology Association meeting on recent progress in predicting N-nitrosamine carcinogenicity potency. The presentation outlines progress over the last year and provides an update on different collaborative working groups, including a recently announced EMA-MutAmind project funded by the European Medicine’s Agency and led …

Predicting toxicity using read-across

Read-across is an example of a flexible in silico toxicology methodology whereby a toxicity prediction for a chemical (often referred to as the target compound) is made using experimental data on one or more similar analogs (often referred to as source compound(s)). This is a lengthy process highly reliant on an expert review of the …

In silico applications in the assessment of Extractables and Leachables

The Product Quality Research Institute (PQRI) recently published on their recommendations for safety thresholds and best practices for extractables and leachables (E&L) in Parenteral Drug products1. The publication describes, and addresses, issues related to the definition and procedures for defining safety thresholds. Within the document, areas of application for in silico methods are also defined. …

Neurotoxicity hazard assessment framework that integrates in silico approaches

This week we are pleased to welcome Dr. Kevin Crofton and Dr. Arianna Bassan as guest contributors to the blog. Within the in silico toxicology project, a position paper on neurotoxicity is appearing in a special issue of the journal of Computational Toxicology1. This paper discusses the need for the development of more informative new …

A protocol to support the weight-of-evidence for human carcinogenicity assessment of pharmaceuticals

This week we are pleased to welcome Dr. Arianna Bassan as a guest contributor to the blog. The recently published draft addendum of the ICH S1B guideline1 introduces a weight-of-evidence (WoE) approach to assess human carcinogenic potential of small molecule pharmaceuticals and determine whether a 2-year rat carcinogenicity study would add value. Application of this …

In Silico Methods for Predicting Drug Toxicity, Second Edition

In Silico Methods for Predicting Drug Toxicity, edited by Emilio Benfenati1 addresses new in silico methodologies, their integrated use, and regulatory implications for the assessment of pharmaceuticals. The second edition contains both updated and new chapters, reflecting advancements in computational toxicology.  Each chapter covers specific areas such as the use of modeling a pharmaceutical in …

New book on mutagenic impurities

We were delighted to contribute to a new book on Mutagenic Impurities, edited by Andrew Teasdale – “Mutagenic Impurities: Strategies for Identification and Control”.1 The book incorporates a discussion on the ICH M7 guideline and covers the in silico assessment of mutagenicity, including the use of structure-activity relationship methodologies, to support the evaluation of impurities. …

Predicting the 6-pack

The 6-pack provides information on health hazards from short-term exposure to a test substance. It is a battery of in vivo tests that evaluate 1) acute systemic toxicity by different routes of exposure (i.e., oral, inhalation and dermal); 2) skin and eye irritation/corrosion; 3) dermal sensitization. It is used in the assessment of many products …

Improving the prediction of bioactivation in relation to drug-drug interactions using proprietary data

The bioactivation of drugs may result in the generation of reactive metabolites that irreversibly inactivate cytochrome P450 (requiring synthesis of new enzyme for recovery of activity). This process is referred to as mechanism-based inhibition (MBI) or time-dependent inhibition and is often involved in damaging drug-drug interactions (DDIs). Within the FDA guidance “In Vitro Drug Interaction …